Trastuzumab Deruxtecan Anti-cancer and Anti-tumor Drugs

Trastuzumab Deruxtecan Anti-cancer and Anti-tumor Drugs

English name:Trastuzumab Deruxtecan
CAS number:1826843-81-5
Another name:Trastuzumab Deruxtecan;Trastuzumab deruxtecan (solution);Fam-trastuzumab deruxtecan;DS-8201a|||VRN-101099|||DS 8201|||T-DXd;Enhertu;Trastuzumab deruxtecan (ADC)
Send Inquiry

Products Description

 

English name:Trastuzumab Deruxtecan

CAS number:1826843-81-5

molecular formula:

Molecular weight: 0

EINECS No.:

Related categories: Pharmaceutical raw materials

The Mol file: Mol File

constitutional formula:

Trastuzumab Deruxtecan Nature

Storage conditions: Solution, -20 C, 2 years

Dissolution: degrees dissolve in acetonitrile

Form: solid

Color: white to off-white

 

Trastuzumab Deruxtecan Use and synthesis method

 

Bioactivity

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER 2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan Composed of a humanized anti-HER 2 antibody, a peptide adaptor for enzymatic cleavage, and a topoisomerase I inhibitor. Trastuzumab deruxtecan Can be used to study HER 2-positive breast cancer and gastric cancer.

 

In vitro study

Trastuzumabderuxtecan(1pM-10nM;5days)inhibitsthegrowthofHER2‐positiveKPL‐4cells,withanIC50of109.7pM.TrastChemicalbookuzumabderuxtecan(10nM;5days)showsbystanderkillingeffectsinHER2‐negativeMDA‐MB‐468cells.CellViabilityAssay

Cell Line: KPL‐4 and MDA‐MB‐468 cells

Concentration: 1, 10, 100, 1000, 10000 pM

Incubation Time: 5 days

Result: Killed both HER2‐positive KPL‐4 cells and HER2‐negative MDA‐MB‐468 cells.

 

In vivo research

Trastuzumab deruxtecan (3 mg/kg; a single i.v.) shows antitumor activity against not only HER2‐positive tumors but also HER2‐negative tumors under the co‐inoculated condition.

Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model.

AnimalModel:FemaleBALB/cnudemiceinjectedwithNCI‐N87andMDA‐MB‐468‐Luc cells

Dosage:3mg/kg

Administration:Asinglei.v

Almost all of the HER2‐positive and HER‐negative cells disappeared and there were little or no cancer cells

Result:

remaining in the tumors.

 

Security information

MSDS information

 

Hot Tags: trastuzumab deruxtecan anti-cancer and anti-tumor drugs, China trastuzumab deruxtecan anti-cancer and anti-tumor drugs suppliers, 216974-75-3, 331731-18-1, 205923-56-4, 1380723-44-3, Daratumumab monoclonal antibody, 845771-78-0